ANIX - NASDAQ

Anixa Biosciences, Inc.

Anixa Biosciences, Inc.

ANIX·NASDAQ

$2.61

+3.6%
HealthcareBiotechnology

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$87.51M
EPS-0.3400
P/E Ratio-7.68
Earnings Date06/03/2026
-7.17M
Operating Cash Flow
-2%
3Y+10.0%
5Y+16.0%
10Y+112.0%
4.87M
Investing Cash Flow
14%
3Y-145.0%
5Y-1691.0%
10Y+224.0%
2.28M
Financing Cash Flow
-33%
3Y+404.0%
5Y-76.0%
10Y-85302.0%
ANIX

Anixa Biosciences, Inc. Cash Conversion Engine

ANIX · NASDAQ
Net Income-11.03M
Depreciation & Amortization-107.00K
Stock-Based Compensation3.68M
Change in Working Capital152.00K
Others129.00K
Capital Expenditures0.00
Free Cash Flow-7.17M

Cash Flow Quality Analysis

FCF Conversion Rate

65.0%

Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.

FCF Growth Trend

+2.2%

Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.

Working Capital Impact

+$152.00K

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

Anixa Biosciences, Inc. Cash Flow Statement

ANIX • NASDAQ

Anixa Biosciences, Inc. Cash Flow StatementOct 2025Oct 2024Oct 2023Oct 2022Oct 2021Oct 2020Oct 2019Oct 2018Oct 2017Oct 2016Oct 2015Oct 2014Oct 2013Oct 2012Oct 2011Oct 2010Oct 2009Oct 2008Oct 2007Oct 2006
OPERATING ACTIVITIES
Net Income
-11M
-12.7M
-9.9M
-13.8M
-13.1M
-10.1M
-11.8M
-14.2M
-5M
-5M
-1.4M
-9.6M
-10.1M
-4.3M
-7.4M
-5.2M
-16.5M
-3.2M
-5.5M
-7.6M
Depreciation & Amortization
-107K
37K
46K
42K
60K
90.2K
466.3K
343.7K
368.5K
358.6K
325.3K
314.5K
991.2K
7.2K
8K
8.4K
10.6K
0.0
9.9K
15.1K
Change in Deferred Taxes
0.0
0.0
0.0
0.0
0.0
0.0
0.0
647.6K
45.9K
0.0
0.0
3.4M
61.9K
126.5K
-30.2K
5.2M
9.4M
0.0
0.0
0.0
Stock-Based Compensation
3.7M
4.4M
4.4M
6M
7.5M
3.9M
5.7M
8.9M
1.2M
873.6K
2.7M
3.1M
3.8M
725.3K
2.7M
2.7M
5M
0.0
0.0
0.0
Other Non-Cash Items
129K
380K
313K
752K
549K
362.8K
418.8K
15K
-833.2K
563.1K
622.5K
1.4M
1.4M
1M
1.8M
-5.1M
9.5K
1.6M
3M
5.3M
Change in Working Capital
152K
526K
-1.1M
485K
78K
-459K
478.4K
67.7K
408.2K
-160.6K
-881.7K
-987K
595.8K
-752K
2.2M
64.6K
-343.7K
752.2K
53.5K
421.2K
Cash from Operating Activities
-7.2M
-7.3M
-6.2M
-6.5M
-4.9M
-6.2M
-4.7M
-4.3M
-3.8M
-3.4M
1.4M
-2.4M
-3.2M
-3.1M
-716K
-2.4M
-2.5M
-901.9K
-2.4M
-1.8M
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-15.8K
-175.5K
-38.4K
-30.2K
-146.5K
-54.8K
-6.7K
(0.0)
-1.6K
-9K
-2.1K
-1.9K
-13.9K
-13.5K
-11K
Acquisitions, Net
(0.0)
(0.0)
(0.0)
(0.0)
(7K)
(5M)
(3.9M)
(4.3M)
(45K)
(1.9M)
(2.9M)
(0.0)
(0.0)
-1K
-118.8K
-51.8K
-61.7K
-19.1M
(0.0)
-110K
Purchase of Investments
-44.4M
-63.8M
-44.4M
-22.5M
-16.5M
-5M
-3.9M
-4.3M
-5.5M
-1.9M
-2.9M
-5.2M
-250K
-1.2M
-3.9M
-749.9K
-2.9M
-999.5K
-825K
-398K
Sale/Maturity of Investments
49.2M
68M
38.8M
11.8M
12.5M
4.7M
3.5M
5.8M
2.8M
3.6M
3M
2.7M
750K
2.9M
1.8M
1.6M
4.4M
2.1M
463K
760.8K
Other Investing Items
0.0
0.0
0.0
0.0
35K
-5M
-3.9M
-4.3M
45K
-1.9M
-2.9M
-6.7K
-676.0
1K
118.8K
51.8K
61.7K
0.0
0.0
0.0
Cash from Investing Activities
(4.9M)
(4.3M)
-5.6M
-10.7M
-3.9M
-305.8K
-525.5K
(1.5M)
-2.7M
(1.5M)
(45.2K)
-2.5M
(499.3K)
(1.7M)
-2.1M
(799.7K)
(1.5M)
-18M
-375.5K
(241.8K)
FINANCING ACTIVITIES
Net Issuance of Common Stock
2.3M
2.9M
0.0
0.0
31.1M
9.3M
5.5M
2.5M
10.9M
0.0
-445.3K
3.7M
1.1M
0.0
1.3M
0.0
0.0
16.2M
2.2M
2.4M
Net Issuance of Debt
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
3.3M
1.8M
750K
0.0
0.0
0.0
0.0
0.0
0.0
Cash Paid for Dividends
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-851.0
-13.5K
-33.5K
-68.2K
-29.5K
(0.0)
(0.0)
(0.0)
Share Repurchases
(0.0)
-6K
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-500K
(11.8K)
-445.3K
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
Other Financing Items
0.0
466K
366K
452K
440K
140.7K
175.2K
58.1K
7.4M
-2.7K
44.6K
375.9K
1.5M
221.9K
1.3M
1.3M
2M
2.5M
0.0
0.0
Cash from Financing Activities
2.3M
3.4M
366K
452K
31.6M
9.4M
5.7M
2.5M
7.4M
-2.7K
-400.6K
7.3M
3.2M
958.5K
2.5M
1.2M
2M
18.7M
2.2M
2.4M
CASH FLOW SUMMARY
Net Change in Cash
-27K
356K
-11.4M
-16.8M
22.7M
2.9M
435.7K
-283.5K
851.1K
-1.9M
1M
2.5M
558.5K
-434.3K
-320.1K
-357.1K
972.6K
-190.5K
-612.5K
775.1K
Cash at Beginning of Period
1.3M
915K
12.4M
29.1M
6.4M
3.5M
3.1M
3.3M
2.5M
4.4M
3.4M
898.2K
339.7K
774K
1.1M
1.5M
478.6K
669.1K
1.3M
506.5K
Cash at End of Period
1.2M
1.3M
915K
12.4M
29.1M
6.4M
3.5M
3.1M
3.3M
2.5M
4.4M
3.4M
898.2K
339.7K
774K
1.1M
1.5M
478.6K
669.1K
1.3M
Free Cash Flow
-7.2M
-7.3M
-6.2M
-6.5M
-4.9M
-6.2M
-4.9M
-4.3M
-3.8M
-3.5M
1.3M
-2.4M
-3.2M
-3.1M
-725K
-2.4M
-2.5M
-915.7K
-2.4M
-1.9M

SEC Filings

ANIX - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

March 11, 2026
March 10, 2026
2026
View Filing
10-Q

10-Q 2026 Q1

Q1

March 09, 2026
January 31, 2026
2026
View Filing
8-K

8-K 2026

N/A

February 09, 2026
February 09, 2026
2026
View Filing
DEF 14A

DEF 14A 2026

N/A

January 28, 2026
January 28, 2026
2026
View Filing
10-K

10-K 2025 FY

FY

January 12, 2026
October 31, 2025
2025
View Filing
8-K

8-K 2025

N/A

December 12, 2025
December 11, 2025
2025
View Filing
10-Q

10-Q 2025 Q3

Q3

September 10, 2025
July 31, 2025
2025
View Filing
S-3

S-3

N/A

September 10, 2025
September 10, 2025
 
View Filing
10-Q

10-Q 2025 Q2

Q2

May 28, 2025
April 30, 2025
2025
View Filing
8-K

8-K 2025

N/A

March 21, 2025
March 20, 2025
2025
View Filing
Showing 1 to 10 of 302 filings

Related Guides

Blog Categories

Continue your ANIX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.